# Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

> **NCT02163824** · PHASE3 · COMPLETED · sponsor: **Kala Pharmaceuticals, Inc.** · enrollment: 380 (actual)

## Conditions studied

- Ocular Infections, Irritations and Inflammations

## Interventions

- **DRUG:** KPI-121 0.25%
- **DRUG:** KPI-121 1.0%
- **DRUG:** Vehicle of KPI-121 0.25%
- **DRUG:** Vehicle of KPI-121 1.0%

## Key facts

- **NCT ID:** NCT02163824
- **Lead sponsor:** Kala Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163824, "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02163824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*